Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.

Expert review of anti-infective therapy - 1 Jan 2015

Akamatsu Nobuhisa, Sugawara Yasuhiko, Kokudo Norihiro

Abstract excerpt

Asunaprevir, a second-generation NS3 protease inhibitor of hepatitis C virus (HCV), exhibits strong antiviral activity against HCV genotypes 1 and 4, but relatively weak activity against genotypes 2 and 3. For chronic HCV infection, asunaprevir with daclatasvir as an interferon-free dual treatment achieves a sustained virologic response of nearly 90% in genotype 1b, and a triple regimen with beclabuvir achieves...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Therapy, Combination
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoquinolines

Share to Protease Inhibitors

Share to Pyrrolidines

Share to Sulfonamides

Share to Valine

Source

Identifiers

PMID: 26414905
DOI: 10.1586/14787210.2015.1091724

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.PMID 26414905Read ↗

Asunaprevir for hepatitis C: a safety evaluation.Semantic proximity Read ↗

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.Semantic proximity Read ↗

Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.Semantic proximity Read ↗

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Daclatasvir + asunaprevir: first global approval.Semantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.Semantic proximity Read ↗

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.Semantic proximity Read ↗

Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.Semantic proximity Read ↗

A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.